5 Best Rising Stocks For 2014

Check out Jim Cramer's latest trading recommendations on "Action Alerts Plus". (Updates from 10:32 a.m. ET with closing information.)

NEW YORK (TheStreet) -- Here's what Jim Cramer had to say on CNBC's "Squawk on the Street" Friday.

Cramer said Verizon (VZ) keeps getting the love from analysts, this time from Deutsche Bank, which upgraded the stock to buy from hold. VZ closed up 2.3% to $50.01.

Advanced Micro Devices (AMD) missed on earnings. Cramer said it was a bad report, mainly due to poor PC sales. AMD dropped 13.7% to $3.53. Baker Hughes (BHI) reported a "magnificent number," according to Cramer. He thinks the company may have finally gotten it together. BHI jumped 7.3% to $55.55. Raymond James downgraded Baxter International (BAX) to hold from buy. Cramer said it makes sense for the company to split up since it essentially has two different businesses. BAX closed 1.8% lower at $66. Amazon (AMZN) is higher because UBS said e-commerce is doing well, contradicting what eBay (EBAY) said on its conference call. Cramer suggested that perhaps "it's raining on eBay's side of the street." AMZN rose 5.8% to $328.93. Cantor Fitzgerald downgraded UnitedHealth Group (UNH) to hold from buy. Cramer said the company reported surprisingly poor earnings results. UNH fell 3.7% to $68.76. To sign up for Jim Cramer's free Booyah! newsletter, with all of his latest articles and videos, please click here. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell

Top 10 High Tech Stocks For 2015: Immunomedics Inc.(IMMU)

Immunomedics, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the United States and Europe. The company?s products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study completed product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib/II clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. Its early phase clinical trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug conjugate therapy. The com pany also develops Dock-and-Lock methodology for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, primarily different solid cancers. In addition, it markets and sells a diagnostic product, LeukoScan, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. Immunomedics, Inc. has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd., to develop vaccines against cancers that include melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of Immunomedics (NASDAQ: IMMU  ) , a biopharmaceutical company researching monoclonal, antibody-based products to treat cancer and other autoimmune disorders, jumped as much as 15% after providing a clinical update on its antibody-drug conjugate programs.

• [By Roberto Pedone]

  Another under-$10 stock that's starting to move within range of triggering a big breakout trade is Immunomedics (IMMU), which is focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. This stock is off to a very bullish start in 2013, with shares up sharply by 110%.

  If you take a look at the chart for Immunomedics, you'll notice that this stock has been uptrending decent for the last month, with shares moving higher from its low of $4.85 to its recent high of $6.54 a share. During that uptrend, shares of IMMU have been consistently making higher lows and higher highs, which is bullish technical price action. This uptrend is coming after shares of IMMU downtrended during July from $6.91 to that $4.65 a share low. Shares of IMMU are now starting to push within range of triggering a big breakout trade.

  Market players should now look for long-biased trades in IMMU if it manages to break out above some near-term overhead resistance at $6.54 a share and then once it clears its 52-week high at $6.91 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 1.15 million shares. If that breakout triggers soon, then IMMU will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $8 to $10 a share, or possibly even north of $10 a share.

  Traders can look to buy IMMU off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $5.52 a share or below more support at $5 a share. One can also buy IMMU off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Wallace Witkowski]

  Immunomedics Inc. (IMMU) �shares rose 19% to $6.18 on heavy volume after the small cap biotech said it just started treating patients with its pancreatic cancer drug in a late-stage clinical trial.

• [By Sean Williams]

  In terms of clinical data, small-cap biotechnology company Immunomedics (NASDAQ: IMMU  ) jumped by double digits after reporting early stage, but nonetheless positive, data from its antibody-drug conjugate program. Two of Immunomedics' ADC's, IMMU-130 which is targeted at metastatic colorectal cancer, and IMMU-132, which is being tested on 13 different cancer types, demonstrated tumor shrinkage and some partial responses. We're still a long way from an approval, but ADC's certainly look like one pathway to effectively treating cancer. Make sure this is a company you've added to your Watchlist.

5 Best Rising Stocks For 2014: Noble Energy Inc. (NBL)

Noble Energy, Inc., through its subsidiaries, engages in the acquisition, exploration, development, production, and marketing of crude oil, natural gas, and natural gas liquids in the United States, West Africa, Eastern Mediterranean, the North Sea, and internationally. Its principal projects include the Central DJ Basin properties in the onshore US; Galapagos and Gunflint projects in the deepwater Gulf of Mexico; Tamar project in the offshore Israel; Aseng, Alen, and Diega/Carmen projects in the offshore Equatorial Guinea; and West Africa gas projects located in the offshore Equatorial Guinea and Cameroon. The company was founded in 1932 and is based in Houston, Texas.

Advisors' Opinion:

• [By Lee Jackson]

  Noble Energy Inc. (NYSE: NBL) is a company expected to benefit when Mexico opens the door for exploration and production from outside companies for the first time in 70 years. We recently wrote about other companies looking to cash in on Mexico. Noble also is revving up the spending to take advantage of higher oil prices. The company is expected to spend $2.37 billion this year. The consensus price objective for the stock is $70.50. Investors are paid a 0.5% dividend.

• [By Matt DiLallo]

  Take Noble Energy (NYSE: NBL  ) and Noble Corp (NYSE: NE  ) . If you look at the ticker symbol of each company, you can see how easy it would be to confuse the two. So before you submit that buy order, let's drill down into each company so you can see why you'd want to double check before submitting that buy order.

• [By Taylor Muckerman and Joel South]

  Whether its the Q10 pumps, which can operate on either liquefied or compressed natural gas in lieu of gasoline or diesel, or the solar powered SandCastle PS-2500 sand storage and delivery system, Halliburton has efficiency and the environment on its mind. A Noble Energy (NYSE: NBL  ) vice president even publicly praised the operations and its ability to minimize the company's "footprint both physically and with emissions".

5 Best Rising Stocks For 2014: Goldcorp Incorporated(GG)

Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. It produces and sells gold, silver, copper, lead, and zinc. The company was founded in 1954 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Ben Levisohn]

  The Market Vectors Gold Miners ETF (GDX) has gained 2.6% to $29.85 today at 10:35 a.m., while Barrick Gold (ABX) has climbed 3.2% to $20.30, Goldcorp (GG) has gained 3% to $30.80 and Newmont Mining (NEM) has risen 1.9% to $32.71. The SPDR Gold Shares ETF (GLD) has ticked up 0.2% today.

5 Best Rising Stocks For 2014: PowerShares WilderHill Clean Energy Portfolio (PBW)

PowerShares WilderHill Clean Energy Portfolio (the Fund) is based on the WilderHill Clean Energy Index and seeks investment results that correspond generally to the price and yield (before the Fund�� fees and expenses) of that equity index. The sectors covered by the Fund include Energy-Alternate Sources, Semiconductors, Electrical Components and Equipment, Chemicals, Electric, Electronics, Computers, Auto Parts and Equipment, Biotechnology and Agriculture. PowerShares Capital Management LLC is the Fund's investment adviser.

PowerShares WilderHill Clean Energy Portfolio�� top 10 holdings include SunPower Corp., Class A, Echelon Corp., Cypress Semiconductor Corp., Cree, Inc., First Solar, Inc., OM Group, Inc., Universal Display Corp., KYOCERA Corp. ADR (Japan), Suntech Power Holdings Co., Ltd. ADR (Cayman Islands) and Applied Materials, Inc.

Advisors' Opinion:

• [By Selena Maranjian]

  Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some clean-energy-related stocks to your portfolio, the PowerShares WilderHill Clean Energy Portfolio ETF (NYSEMKT: PBW  ) could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.
  
  The basics
  ETFs often sport lower expense ratios than their mutual fund cousins. The PowerShares ETF's expense ratio -- its annual fee -- is 0.70%. The fund is fairly small, too, so if you're thinking of buying, beware of possibly large spreads between its bid and ask prices. Consider using a limit order if you want to buy in.

• [By Wall Street Sector Selector]

  Another ETF which invests in the solar sector is the PowerShares WilderHill Clean Energy ETF (PBW). Although its holdings are not limited to the solar sector, its most significant holding is SunPower Corporation at 4.96% of the weight. Its number three holding is MEMC Electronic Materials at 3.42% of the weight. PBW's average trading volume is robust at over 400,000 shares per day. Its market cap is $135 million.

• [By Aaron Levitt]

  A lack of profits and the reliance on government subsidies have made most stocks in the renewable energy category pretty poor performers over the years. Just check out the performance of the broad PowerShares WilderHill Clean Energy ETF (PBW). It has lost about 7.5% annually since its inception in 2005.